KR20230079514A - 암 면역요법용 dna 백신을 제조하기 위한 방법 - Google Patents

암 면역요법용 dna 백신을 제조하기 위한 방법 Download PDF

Info

Publication number
KR20230079514A
KR20230079514A KR1020237018125A KR20237018125A KR20230079514A KR 20230079514 A KR20230079514 A KR 20230079514A KR 1020237018125 A KR1020237018125 A KR 1020237018125A KR 20237018125 A KR20237018125 A KR 20237018125A KR 20230079514 A KR20230079514 A KR 20230079514A
Authority
KR
South Korea
Prior art keywords
leu
ser
val
pro
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020237018125A
Other languages
English (en)
Korean (ko)
Inventor
하인즈 루베나우
Original Assignee
엔이씨 온코이뮤니티 에이에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엔이씨 온코이뮤니티 에이에스 filed Critical 엔이씨 온코이뮤니티 에이에스
Priority to KR1020267008900A priority Critical patent/KR20260047288A/ko
Publication of KR20230079514A publication Critical patent/KR20230079514A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001109—Vascular endothelial growth factor receptors [VEGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/001168—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020237018125A 2016-07-13 2017-07-12 암 면역요법용 dna 백신을 제조하기 위한 방법 Ceased KR20230079514A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020267008900A KR20260047288A (ko) 2016-07-13 2017-07-12 암 면역요법용 dna 백신을 제조하기 위한 방법

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP16001550 2016-07-13
EP16001550.9 2016-07-13
PCT/EP2017/067590 WO2018011289A1 (en) 2016-07-13 2017-07-12 Process for the production of a dna vaccine for cancer immunotherapy
KR1020197002050A KR20190027834A (ko) 2016-07-13 2017-07-12 암 면역요법용 dna 백신을 제조하기 위한 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197002050A Division KR20190027834A (ko) 2016-07-13 2017-07-12 암 면역요법용 dna 백신을 제조하기 위한 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020267008900A Division KR20260047288A (ko) 2016-07-13 2017-07-12 암 면역요법용 dna 백신을 제조하기 위한 방법

Publications (1)

Publication Number Publication Date
KR20230079514A true KR20230079514A (ko) 2023-06-07

Family

ID=56418345

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020237018125A Ceased KR20230079514A (ko) 2016-07-13 2017-07-12 암 면역요법용 dna 백신을 제조하기 위한 방법
KR1020197002050A Ceased KR20190027834A (ko) 2016-07-13 2017-07-12 암 면역요법용 dna 백신을 제조하기 위한 방법
KR1020267008900A Pending KR20260047288A (ko) 2016-07-13 2017-07-12 암 면역요법용 dna 백신을 제조하기 위한 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020197002050A Ceased KR20190027834A (ko) 2016-07-13 2017-07-12 암 면역요법용 dna 백신을 제조하기 위한 방법
KR1020267008900A Pending KR20260047288A (ko) 2016-07-13 2017-07-12 암 면역요법용 dna 백신을 제조하기 위한 방법

Country Status (13)

Country Link
US (2) US10821163B2 (cg-RX-API-DMAC7.html)
EP (1) EP3484503A1 (cg-RX-API-DMAC7.html)
JP (2) JP7098599B2 (cg-RX-API-DMAC7.html)
KR (3) KR20230079514A (cg-RX-API-DMAC7.html)
CN (1) CN109475614A (cg-RX-API-DMAC7.html)
AU (1) AU2017295004B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019000657A2 (cg-RX-API-DMAC7.html)
CA (1) CA3028549A1 (cg-RX-API-DMAC7.html)
IL (1) IL263568A (cg-RX-API-DMAC7.html)
MX (1) MX2019000415A (cg-RX-API-DMAC7.html)
RU (1) RU2019100079A (cg-RX-API-DMAC7.html)
SG (1) SG11201811258UA (cg-RX-API-DMAC7.html)
WO (1) WO2018011289A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190117603A (ko) 2017-02-17 2019-10-16 백심 아게 신규 vegfr-2 표적화 면역요법상 접근법
WO2019014398A1 (en) 2017-07-11 2019-01-17 Actym Therapeutics, Inc. MODIFIED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOF
CA3176812A1 (en) 2018-07-11 2020-01-16 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
US20210213121A1 (en) * 2018-09-05 2021-07-15 Vaximm Ag Neoantigen targeting dna vaccine for combination therapy
KR20220004959A (ko) 2019-02-27 2022-01-12 액팀 테라퓨틱스, 인코퍼레이티드 종양, 종양-상주 면역 세포, 및 종양 미세환경을 콜로니화하기 위해 조작된 면역자극성 박테리아
AU2021208400A1 (en) 2020-01-13 2022-08-11 Vaximm Ag Salmonella-based DNA vaccines in combination with an antibiotic
US20250340919A1 (en) * 2022-06-30 2025-11-06 Shimadzu Corporation Method for Preparing Analysis of Microorganisms, and Method for Analyzing Microorganisms

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013091898A1 (en) 2011-12-22 2013-06-27 Vaximm Ag Method for producing high yield attenuated salmonella strains

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2714071T (lt) * 2011-05-24 2019-10-10 Biontech Rna Pharmaceuticals Gmbh Individualizuotos vakcinos nuo vėžio
SG11201500054QA (en) * 2012-07-05 2015-03-30 Vaximm Ag Dna vaccine for use in pancreatic cancer patients
DK2988762T3 (en) * 2013-04-25 2018-07-16 Vaximm Ag SALMONELLA-BASED VECTORS FOR CANCER IMMUNITY TARGET TARGETED WILMS 'TUMORGEN WT1
PL3082850T3 (pl) 2013-12-18 2020-01-31 Vaximm Gmbh Celowana szczepionka DNA MSLN w immunoterapii nowotworu
JP7060324B2 (ja) * 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013091898A1 (en) 2011-12-22 2013-06-27 Vaximm Ag Method for producing high yield attenuated salmonella strains

Also Published As

Publication number Publication date
BR112019000657A2 (pt) 2019-04-24
KR20190027834A (ko) 2019-03-15
IL263568A (en) 2019-01-31
WO2018011289A1 (en) 2018-01-18
JP2019521154A (ja) 2019-07-25
JP2022097591A (ja) 2022-06-30
RU2019100079A (ru) 2020-08-13
US10821163B2 (en) 2020-11-03
CN109475614A (zh) 2019-03-15
US11590215B2 (en) 2023-02-28
JP7098599B2 (ja) 2022-07-11
AU2017295004A1 (en) 2019-01-03
EP3484503A1 (en) 2019-05-22
SG11201811258UA (en) 2019-01-30
US20220072112A1 (en) 2022-03-10
US20190183996A1 (en) 2019-06-20
CA3028549A1 (en) 2018-01-18
AU2017295004B2 (en) 2020-08-13
KR20260047288A (ko) 2026-04-07
MX2019000415A (es) 2019-03-28

Similar Documents

Publication Publication Date Title
AU2017295004B2 (en) Process for the production of a DNA vaccine for cancer immunotherapy
KR102090612B1 (ko) 췌장암 환자용 dna 백신
CN107995868B (zh) 用于联合治疗的vegfr-2靶向dna疫苗
KR20190125481A (ko) 암의 면역요법을 위한 신규 pd-l1 표적화 dna 백신
AU2018222777B9 (en) Novel VEGFR-2 targeting immunotherapy approach
JP2024167172A (ja) 併用療法用dnaワクチンを標的とするネオアンチゲン
CN109906087A (zh) 用于联合治疗的wt1靶向dna疫苗
KR20220161444A (ko) 새로운 살모넬라-기반의 코로나바이러스 백신
RU2759227C2 (ru) ДНК-вакцина против вируса SARS-CoV-2 на основе генотерапевтического ДНК-вектора GDTT1.8NAS12, способ ее получения, штаммы, несущие генотерапевтические ДНК-вектора, способ их получения, способ производства в промышленных масштабах генотерапевтических ДНК-векторов
KR20220128638A (ko) 항생제와 조합되는 살모넬라-기반의 dna 백신
CN120944823A (zh) 特异性结合Claudin18.2的嵌合抗原受体免疫细胞及其应用

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B17 Application discontinued following pre-grant review

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B17-REX-PX0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

V11 Administrative appeal requested

Free format text: ST27 STATUS EVENT CODE: A-3-3-V10-V11-APL-PJ0201 (AS PROVIDED BY THE NATIONAL OFFICE)